文献速递血栓与止血

血友病B患者接受etranacogene dezaparvovec基因治疗3年后凝血因子IX水平稳定持久

Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy.
PubMed 文献 · Blood Adv · 2023-01-01

这项2b期、开放标签、单次给药、单臂、多中心试验纳入3例凝血因子IX≤2%的重度或中重度血友病B成人患者,单次静脉给予etranacogene dezaparvovec 2×10^13基因拷贝/kg。6周时凝血因子IX活性≥5%的主要终点达到,第1年平均40.8%、第3年维持36.9%,全部患者停止凝血因子IX预防治疗,3年内无临床显著肝酶升高、无需激素、无抑制物产生及迟发安全性事件。

要点

  • 3例患者单次静脉给予2×10^13基因拷贝/kg后,凝血因子IX活性第1年平均40.8%、第3年36.9%。
  • 全部患者停止凝血因子IX预防治疗,3例中2例出血完全消除。
  • 3年内无临床显著肝酶升高、无需激素、无凝血因子IX抑制物产生及迟发安全性事件。

核心结论

  • 在血友病B成人患者中,etranacogene dezaparvovec给药后3年内安全有效。

研究设计与样本

  • 2b期、开放标签、单次给药、单臂、多中心试验,纳入3例凝血因子IX≤2%的重度或中重度血友病B成人患者。
  • 全部参与者(n=3)接受单次静脉剂量2×10^13基因拷贝/kg,计划随访5年。
  • 试验注册号NCT03489291。

主要发现

  • 6周时凝血因子IX活性≥5%的主要终点达到。
  • 凝血因子IX活性第1年平均40.8%,第3年维持于36.9%。
  • 全部参与者停止凝血因子IX预防治疗;3例中2例出血完全消除。
  • 1例参与者因择期手术、2次报告出血事件及2次因未报告原因自行单次输注而按方案接受按需凝血因子IX替代治疗。
  • 1例参与者在给药后不久出现2次轻度、自限性不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Etranacogene dezaparvovec (AMT-061) is a recombinant adeno-associated virus serotype 5 (AAV5) vector containing a codon-optimized Padua variant human factor IX (FIX) transgene with a liver-specific promoter. Here, we report 3-year outcomes from a phase 2b, open-label, single-dose, single-arm, multicenter trial conducted among adults with severe or moderately severe hemophilia B (FIX ≤2%). All participants (n = 3) received a single intravenous dose (2 × 1013 gene copies per kg) and will be followed up for 5 years. The primary end point of FIX activity ≥5% at 6 weeks was met. Secondary end points included bleed frequency, FIX concentrate use, joint health, and adverse events (AEs). All participants required routine FIX prophylaxis and had neutralizing antibodies to AAV5 before etranacogene dezaparvovec treatment. After administration, FIX activity rose to a mean of 40.8% in year 1 and was sustained in year 3 at 36.9%. All participants discontinued FIX prophylaxis. Bleeding was completely eliminated in 2 out of 3 participants. One participant required on-demand FIX replacement therapy per protocol because of elective surgical procedures, for 2 reported bleeding episodes, and twice for a single self-administered infusion because of an unreported reason. One participant experienced 2 mild, self-limiting AEs shortly after dosing. During the 3-year study period, there were no clinically significant elevations in liver enzymes, no requirement for steroids, no FIX inhibitor development, and no late-emergent safety events in any participant. Etranacogene dezaparvovec was safe and effective in adults with hemophilia B over 3 years after administration. This trial was registered at www.clinicaltrials.gov as #NCT03489291.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. von Drygalski A, Gomez E, Giermasz A, et al. Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy. Blood Adv. 2023. PMID: 36490302. doi:10.1182/bloodadvances.2022008886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。